after a major phase iii clinical trial for alzheimer s disease ad treatment failed to show any benefit three other ad trials continued major industry based development in this indication essentially stopped after another phase iii trial suffered the same fate in 2012 latrepirdine failed in the phase iii trial for huntington disease latrepirdine is an orally active small molecule compound that has been shown to inhibit brain cell death in animal models of alzheimer s disease and huntington s disease research suggests it may also have cognition enhancing effects in healthy individuals in the absence of neurodegenerative disease pathology however because of negative results in human clinical trials the drug remains unlicensed for any neurodegenerative condition latrepirdine attracted renewed interest in 2009 after being shown in small preclinical trials to have positive effects on persons suffering from alzheimer s disease animal studies showing potential beneficial effects on alzheimer s disease models were shown in russian research in 2000 preliminary results from human trials have also been promising in an initial six month phase ii trial results have shown significant improvement over placebo at 12 months latrepirdine showed promising results in a phase iii equivalent double blind trial in russia